Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127141342 | 12714134 | 2 | F | 20160826 | 20160905 | 20160923 | PER | US-PFIZER INC-3081221 | PFIZER | 48.00 | YR | F | Y | 57.00000 | KG | 20160923 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127141342 | 12714134 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | 3 ROUNDS | U | 76517 | SOLUTION FOR INJECTION | |||||||||
| 127141342 | 12714134 | 2 | SS | AVASTIN | BEVACIZUMAB | 1 | 3 ROUNDS | U | 0 | ||||||||||
| 127141342 | 12714134 | 3 | SS | TAXOL | PACLITAXEL | 1 | 3 ROUNDS | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127141342 | 12714134 | 1 | Lung adenocarcinoma stage IV |
| 127141342 | 12714134 | 2 | Lung adenocarcinoma stage IV |
| 127141342 | 12714134 | 3 | Lung adenocarcinoma stage IV |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127141342 | 12714134 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127141342 | 12714134 | Disease progression | |
| 127141342 | 12714134 | Lung adenocarcinoma stage IV | |
| 127141342 | 12714134 | Sinusitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |